Early Detection of Lung Cancer Treatment Response Using PET Imaging
Author Information
Author(s): Ullrich Roland T., Zander Thomas, Neumaier Bernd, Koker Mirjam, Shimamura Takeshi, Waerzeggers Yannic, Borgman Christa L., Tawadros Samir, Li Hongfeng, Sos Martin L., Backes Heiko, Shapiro Geoffrey I., Wolf Jürgen, Jacobs Andreas H., Thomas Roman K., Winkeler Alexandra
Primary Institution: Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society, Medical Faculty of the University of Cologne, Cologne, Germany
Hypothesis
Can [18F]FLT PET imaging identify early responses to EGFR inhibitors in lung cancer?
Conclusion
[18F]FLT PET imaging can reliably detect early responses to erlotinib treatment in EGFR-dependent lung tumors.
Supporting Evidence
- Erlotinib-sensitive tumors showed a significant decrease in [18F]FLT uptake after two days of treatment.
- The reduction in [18F]FLT PET signal correlated with cell cycle arrest and apoptosis.
- Complete lack of [18F]FLT PET response was observed in tumors with the T790M resistance mutation.
Takeaway
This study shows that a special type of imaging can help doctors see if a lung cancer treatment is working just two days after starting it.
Methodology
The study compared [18F]FLT and [18F]FDG PET imaging to assess treatment response in EGFR-dependent lung cancer models.
Limitations
The study primarily used cell lines and animal models, which may not fully represent human responses.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website